Typical Household Elasticity of Demand for Pharmaceuticals Across European States

• Authors: Agata Żółtaszek

Title variants

PL

Elastyczność popytu na farmaceutyki typowego gospodarstwa domowego w krajach europejskich

Abstracts

PL

Według Światowej Organizacji Zdrowia (WHO) prawie miliard ludzi na całym świecie jest zagrożonych popadnięciem w ubóstwo z powodu wydatków na zdrowie, a farmaceutyki są integralną częścią rosnącego problemu. Niniejsze badanie ma na celu ocenę elastyczności cenowej i dochodowej popytu na leki w państwach europejskich w latach 2009–2019. Przedmiotem analizy jest typowe gospodarstwo domowe w każdym kraju. Analiza koncentruje się na ocenie problemu w świetle wzrostu gospodarczego. W związku z tym wyniki są porównywane według grup rozwoju krajów, aby wskazać wszelkie podobieństwa i różnice wewnątrz klastrów i między nimi. Wyniki wskazują, że gospodarstwa domowe w regionach biedniejszych są bardziej wrażliwe na bodźce ekonomiczne niż w krajach zamożnych. Zarówno elastyczność dochodowa, jak i cenowa wskazują na niezaspokojone zapotrzebowanie na leki z powodu niewystarczających zasobów finansowych. Co więcej, reakcja gospodarstw domowych na zmiany dochodów i cen różni się w zależności od czasu, kraju i klastrów.

EN

According to the World Health Organisation (WHO), almost a billion people worldwide are at risk of falling into poverty due to out‑of‑pocket health spending, and pharmaceuticals are an integral part of this growing problem. The presented study aims to assess the price and income elasticity of demand for pharmaceuticals across European states over the period 2009–2019. The subject of the analysis is a typical household in each state. The analysis focuses on evaluating interactions in the light of economic growth, thus the results are cross‑referenced with the countries’ development groups to pinpoint any similarities and contrasts within and between clusters. The results indicate that households in underprivileged regions have a higher responsiveness to economic stimuli than in prosperous states. Both the income and price elasticities indicate the existence of unmet need for pharmaceuticals due to insufficient financial resources. Moreover, households’ responsiveness to income and price changes varies across time, states and affluence development groups.

Keywords

PL

ekonomia zdrowia; bezpośrednie prywatne wydatki farmaceutyczne; dochodowa elastyczność popytu; cenowa elastyczność popytu; analizy regionalne

EN

health economics; out-of-pocket pharmaceutical expenditures; income elasticity of demand; price elasticity of demand; regional studies

• Publisher: Uniwersytet Łódzki. Wydawnictwo Uniwersytetu Łódzkiego
• Journal: Acta Universitatis Lodziensis. Folia Oeconomica
• Year: 2022
• Volume: 1
• Issue: 358
• Pages: 32-58

Dates

published

2022

Contributors

author

Agata Żółtaszek

• University of Lodz, Faculty of Economics and Sociology, Department of Spatial Econometrics, Lodz, Poland

• https://orcid.org/000000033657288X

References

• Alghanim S.A. (2011), Self-medication practice among patients in a public health care system, “Eastern Mediterranean Health Journal”, vol. 17, no. 5, pp. 409–416.
• Ben-Aharon O., Shavit O., Magnezi R. (2017), Does drug price-regulation affect healthcare expenditures?, “The European Journal of Health Economics”, vol. 18, pp. 859–867, https://doi.org/10.1007/s10198-016-0832-z
• Besanko D., Braeutigam R. (2013), Microeconomics, John Wiley & Sons, Hoboken.
• Bhattacharya J., Hyde T., Tu P. (2013), Health Economics, Macmillan International Higher Education, New York.
• Colorectal cancer burden in EU–27 (2021), European Cancer Information System, European Union, https://ecis.jrc.ec.europa.eu/pdf/Colorectal_cancer_factsheet-Mar_2021.pdf (accessed: 1.08.2021).
• Du J., Yang X., Chen M., Wang Z. (2019), Socioeconomic determinants of out-of-pocket pharmaceutical expenditure among middle-aged and elderly adults based on the China Health and Retirement Longitudinal Survey, “BMJ Open”, vol. 9, pp. 1–13, https://doi.org/10.1136/bmjopen-2018-024936
• Dunphy C., Peterson C., Zhang K., Jones C.M. (2021), Do out-of-pocket costs influence retention and adherence to medications for opioid use disorder?, “Drug and Alcohol Dependence”, vol. 225, pp. 1–5, https://doi.org/10.1016/j.drugalcdep.2021.108784
• Dwivedi D.N. (2002), Microeconomics: Theory And Applications, Pearson Education India, Delhi.
• Eurostat (n.d.), Harmonised Indices of Consumer Prices (HICP) – FAQ, https://ec.europa.eu/eurostat/web/hicp/faq (accessed: 13.08.2021).
• Eurostat (n.d.), Health care expenditure, https://ec.europa.eu/eurostat/cache/metadata/en/hlth_sha11_esms.htm (accessed: 13.08.2021).
• Eurostat Database (n.d.), https://ec.europa.eu/eurostat/data/database (accessed: 1.08.2021).
• Gazaway S.B., Barnett M.D., Bowman E.H., Ejem D., Harrell E.R., Brown C.J., Bakitas M. (2021), Health Professionals Palliative Care Education for Older Adults: Overcoming Ageism, Racism, and Gender Bias, “Current Geriatrics Reports”, no. 10, pp. 148–156, https://doi.org/10.1007/s13670-021-00365-7
• Glied S., Smith P.C. (2013), The Oxford Handbook of Health Economics, Oxford University Press, Oxford.
• Guinness L., Wiseman V . (2011), Introduction To Health Economics, McGraw-Hill Education, Berkshire.
• MacDonald M. (1995), Feminist economics: from theory to research, “Canadian Journal of Economics”, vol. 28, no. 1, pp. 159–176.
• Makowska M., Boguszewski R., Nowakowski M., Podkowińska M. (2020), Self-Medication-Related Behaviors and Poland’s COVID–19 Lockdown, “International Journal of Environmental Research and Public Health”, vol. 17, no. 8344, https://doi.org/10.3390/ijerph17228344
• Matin B.K., Azami S.R., Mahmoudi S., Rezaei S., Shaahmadi F., Karyani A.K. (2015), Determinants of pharmaceutical expenditures of urban households: A time series study in Kermanshah province (Iran), “Electron Physician”, vol. 7, no. 7, https://doi.org/10.19082/1470
• McClellan C., Fingar K.R., Ali M.M., Olesiuk W.J., Mutterd R., Gibson T.B. (2019), Price elasticity of demand for buprenorphine/naloxone prescriptions, “Journal of Substance Abuse Treatment”, vol. 106, pp. 4–11, https://doi.org/10.1016/j.jsat.2019.08.001
• Murphy S.M., Morgan J.R., Jeng P.J., Schackman B.R. (2019), Will converting naloxone to over-the-counter status increase pharmacy sales?, “Health Services Research”, vol. 54, issue 4, pp. 764–772, https://doi.org/10.1111/1475-6773.13125
• O’Brien G.L., McAlister M., Byrne S., Gallagher J. (2020a), Overcoming hurdles: measurement of health-related outcomes associated with national level medicines usage in Ireland, “Drugs in Context”, vol. 9, no. 4–2, https://doi.org/10.7573/dic.2020-4-2
• O’Brien G.L., Sinnott S.-J., O’Flynn B., Walshe V., Mulcahy M., Byrne S. (2020b), Out of pocket or out of control: A qualitative analysis of healthcare professional stakeholder involvement in pharmaceutical policy change in Ireland, “Health Policy”, vol. 124, issue 4, pp. 411–418, https://doi.org/10.1016/j.healthpol.2020.02.011
• OECD (2003), Glossary of statistical terms, https://stats.oecd.org/glossary/ (accessed: 12.08.2021).
• Olsen J.A. (2017), Principles in Health Economics and Policy, Oxford University Press, Oxford.
• Santerre R.E., Vemont J.A. (2006), Assessing Consumer Gains from a Drug Price Control Policy in the United States, “Southern Economic Journal”, vol. 73(1), pp. 233–245.
• Sanwald A., Theurl E. (2017), Out-of-pocket expenditures for pharmaceuticals: lessons from the Austrian household budget survey, “European Journal of Health Economics”, vol. 18, pp. 435–447, https://doi.org/10.1007/s10198-016-0797-y
• Siminski P. (2011), The price elasticity of demand for pharmaceuticals amongst high income older Australians: a natural experiment, “Applied Economics”, vol. 43, pp. 4835–4846.
• Sloan F.A., Hsieh C.-R. (2017), Health Economics, MIT Press, Cambridge.
• WHO (n.d.), Essential medicines, http://www.emro.who.int/health-topics/essential-medicines/index.html (accessed: 16.08.2021).
• WHO (n.d.), European Region Health Expenditure Dashboard, https://www.who.int/health_financing/topics/resource-tracking/European-Region-Health-Expenditure-Dashboard.pdf (accessed: 16.08.2021).
• WHO (n.d.), Global Essential Medicines, https://global.essentialmeds.org/dashboard/countries/97 (accessed: 16.08.2021).
• WHO (n.d.), Global Health Expenditure Database, https://apps.who.int/nha/database/Home/Index/en (accessed: 16.08.2021).
• WHO (n.d.), Global Health Expenditure Database. Health Expenditure Profile, https://apps.who.int/nha/database/country_profile/Index/en (accessed: 16.08.2021).
• WHO (n.d.), Health accounts, https://www.who.int/health-topics/health-accounts#tab=tab_1 (accessed: 16.08.2021).
• WHO (n.d.), Health budget, https://www.who.int/health-topics/health-budget#tab=tab_1 (accessed: 16.08.2021).
• WHO (n.d.), Pharmaceutical products, http://www.emro.who.int/health-topics/pharmaceutical-products/index.html (accessed: 16.08.2021).
• WHO (2000a), Guidelines for the regulatory assessment of medicinal products for use in self-medication, https://apps.who.int/iris/handle/10665/66154 (accessed: 16.08.2021).
• WHO (2000b), WHO report on cancer: setting priorities, investing wisely and providing care for all, Geneva.
• WHO (2001), WHO/WTO Workshop on Pricing and Financing of Essential Drugs, https://www.who.int/news/item/11-04-2001-who-wto-workshop-on-pricing-and-financing-of-essential-drugs (accessed: 25.08.2021).
• WHO (2013), Prequalification of medicines by WHO, https://www.who.int/news-room/fact-sheets/detail/prequalification-of-medicines-by-who (accessed: 16.08.2021).
• WHO (2018), WHO Report: Medicines reimbursement policies in Europe, Geneva.
• WHO (2019), WHO Report: Global spending on health: a world in transition, “WHO/HIS/HGF/HFWorkingPaper”, no. 19.4.
• WHO (2020), WHO Report: Global spending on health 2020: weathering the storm, Geneva.
• WHO (2021a), Cardiovascular diseases (CVDs), https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds) (accessed: 30.07.2021).
• WHO (2021b), Primary health care, https://www.who.int/news-room/fact-sheets/detail/primary-health-care (accessed: 16.08.2021).
• Xu K., Soucat A., Kutzin J., Brindley C., Maele N. van de, Touré H., Aranguren Garcia M., Li D., Barroy H., Flores G., Roubal T., Indikadahena C., Cherilova V., Siroka A. (2018), Public Spending on Health: A Closer Look at Global Trends, ”WHO/HIS/HGF/HF Working Paper”, no. 18.3, World Health Organization, Geneva.

Identifiers

DOI

10.18778/0208-6018.358.03

Biblioteka Nauki

2154146